id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-340516-9dfaqsv7	Moore, Anne C.	Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection	2020-09-06		.txt	text/plain	6679	335	48	We demonstrate that, compared to expression of the S1 domain or a stabilized spike antigen, the full length, wild-type spike antigen induces significantly higher neutralizing antibodies in the periphery and in the lungs, when the vaccine is administered mucosally. Here, we report the induction of neutralizing antibody (Nab), IgG and IgA antibody responses, and T cell responses in mice following immunization of rAd vectors expressing one or more SARS-CoV-2 antigens. We have previously demonstrated that an oral, tableted rAd-based vaccine can induce protection against respiratory infection and shedding following influenza virus challenge 15 as well as intestinal immunity to norovirus antigens in humans 12 . In summary, these studies in mice represent our first step in creating a vaccine candidate, demonstrating the immunogenicity of the construct at even low vaccine doses and the elucidation of the full-length spike protein as a leading candidate antigen to induce T cell responses and superior systemic and mucosal neutralizing antibody.	./cache/cord-340516-9dfaqsv7.txt	./txt/cord-340516-9dfaqsv7.txt